Neurogen halts Phase IIb trial and seeks buyer
This article was originally published in Scrip
Neurogen is cutting staff and winding up operations as it looks for a buyer for its assets or the company as a whole. This is after it failed to find a partner for its lead product candidate
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.